Community/Retail

Elizabeth Thiele, MD, PhD, pediatric neurologist/epileptologist, discusses the impact of tuberous sclerosis complex on children.

Jacqueline A. French, MD—professor of neurology, NYU Comprehensive Epilepsy Study Consortium, president, The Epilepsy Study Consortium—discusses how the new ILAE definition of epilepsy can improve patient outcomes.

Elizabeth Thiele, MD, PhD, pediatric neurologist/epileptologist, discusses symptoms of tuberous sclerosis complex and the role early detection plays in disease prognosis.

For the first time, the new International League Against Epilepsy (ILAE) seizure classifications were presented at the American Epilepsy Society conference during the Annual Fundamentals Symposium: The New Definition and Classification of Epilepsy on Friday, December 2, 2016.

The definition of epilepsy has been updated by the International League Against Epilepsy.

Speakers discuss the state of epilepsy care around the world at the AES conference.

Elizabeth Thiele, MD, PhD--pediatric neurologist/epileptologist, director, The Carol and James Herscot Center for Children and Adults with TSC, Massachusetts General Hospital--discusses tuberous sclerosis complex.

The Addiction Treatment Advisory Group (ATAG), created last year by the Academy of Managed Care Pharmacy (AMCP), has released detailed findings on how managed care organizations can better address the opioid addiction crisis, including through improved access to naloxone and Medication Assisted Therapies (MAT).

The National Association of Chain Drug Stores (NACDS) today expressed appreciation to Congressional leaders for advancing the final National Defense Authorization Act (NDAA) that includes the NACDS-supported “Pilot Program for Prescription Drug Acquisition Cost Parity in the TRICARE Pharmacy Benefits Program.”

The FDA has approved a new indication for Boehringer Ingelheim’s empagliflozin (Jardiance), allowing it to be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.

The FDA has green-lighted the Abbreviated New Drug Application (ANDA) for armodafinil tablets.

In this week's "Around the Web," Pharmacy Times presents a video that was recently posted by the World Health Organization, which discusses self-testing options for HIV.

A hormone produced in the venom of the platypus and echidnas holds future potential to provide clues about treating diabetes, according to a study published in the Nature journal Scientific Reports.

MDMA, better known as ecstasy or “Molly” and 3,4-methylenedioxymethamphetamine, is predominantly dismissed as an illicit street drug abused by raucous club-goers.

A recently-published study explores the outcomes associated with the combination of DOACs and dual anti platelet therapy.

CDC officials now recommend routine use of the meningococcal conjugate vaccine for patients with HIV.

Many students apply for pharmacy residencies without understanding their benefits and disadvantages.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Egalet has submitted a supplemental new drug application (sNDA) to the FDA for Oxaydo, (oxycodone HCl, USP) in favor of an abuse-deterrent label claim for the intravenous route of abuse.

Founding partners of the Next-Generation Pharmacist awards Parata Systems and Pharmacy Times, the leading media resource for pharmacists and the pharmacy industry, are now accepting nominations for the 2017 awards program.

The FDA has approved Relypsa, Inc.’s supplemental New Drug Application (sNDA) with label updates of Veltassa (patiromer) for oral suspension. Veltassa was approved by the FDA for the treatment of hyperkalemia on October 21, 2015.

Flu vaccinations during pregnancy do not seem to increase risk of autism spectrum disorders in children, according to a report published in JAMA Pediatrics.

December 1 is observed as World AIDS Day.

A study that evaluated a phase 3 monoclonal antibody treatment that targeted Alzheimer’s disease, solanezumab (Eli Lilly), did not meet its primary endpoint in the EXPEDITION3 clinical trial, according to a statement from the company.

One entrepreneurial student had his first experience with pharmacy in high school, is that where we should be starting?

Opportunities for Ohioans with Disabilities has recognized Meijer as a Champion of Opportunity for its commitment and leadership in integrating individuals with disabilities into Ohio’s workforce.

According to the CDC, 82% of American adults take at least one medication and 29% take five or more.

​Albertsons Companies will have its name in lights on the University of Idaho campus with a commitment of $500,000 over the next 10 years to the new court-sports arena and naming rights to the scoreboard.